RxDoctor Payments Data

Rosemary Fine, NP

Nurse Practitioner · New Hyde Park, NYNPI 1558870162

Payments from drug & device makers

$858in general payments, 2019–2025

Across 16 payments — averaging $53.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$351
  • Beigene USA, Inc.$125
  • E.r. Squibb & Sons, L.L.C.$122
  • Astellas Pharma US Inc$99
  • Novartis$58
  • Rigel Pharmaceuticals, Inc.$51
  • plus $51 from 2 others

What the payments were for

  • Food & beverage$38745%
  • Education$47155%

General payments by program year

21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$858 in reported general payments places this provider in the 85th percentile of 4,112 nurse practitioner providers in New York.

See all nurse practitioner providers in New York

Medicare billing

Part B allowed, 2024
$32,085
Medicare patients
129
Services billed
732

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ImbruvicaIbrutinib44$864,440
RevlimidLenalidomide39$770,699
Lenalidomide34$501,908
PomalystPomalidomide17$383,086
TavalisseFostamatinib Disodium12$171,931
Abiraterone Acetate13$36,669
EliquisApixaban34$27,169
XareltoRivaroxaban19$26,438
Enoxaparin Sodium11$3,428
Hydroxyurea60$1,439
Anastrozole18$338
Tramadol Hcl11$90
Prednisone20$85
Warfarin Sodium13$41

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Bristol Myers SquibbRevlimid$14$770,69939 claims
E.r. Squibb & Sons, L.L.C.Pomalyst$122$383,08617 claims
Rigel Pharmaceuticals, Inc.Tavalisse$51$171,93112 claims
PfizerEliquis$37$27,16934 claims
Johnson & JohnsonXarelto$351$26,43819 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 4,112 nurse practitioner providers in New York.

Other nurse practitioner in New Hyde Park

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →